Clinical evaluation of the iXip index to reduce prostate re-biopsies
- 1 January 2018
- journal article
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 16, 59-63
Abstract
No abstract availableKeywords
Funding Information
- Xeptagen S.p.A
This publication has 10 references indexed in Scilit:
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative IntentEuropean Urology, 2017
- Repeat Prostate Biopsy: Rationale, Indications, and StrategiesEuropean Urology Focus, 2015
- Addressing the need for repeat prostate biopsy: new technology and approachesNature Reviews Urology, 2015
- EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised DiseaseEuropean Urology, 2011
- Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patientsCancer Detection Prevention, 2007
- THE OCCURRENCE OF PROSTATE-SPECIFIC ANTIGEN - IGM IMMUNE COMPLEXES (IC) AS NOVEL SERUM BIOMARKER FOR PROSTATE CANCEREuropean Urology Supplements, 2006
- Statistics review 14: Logistic regressionCritical Care, 2005
- Case-control study of screening for prostatic cancer by digital rectal examinationsThe Lancet, 1991
- Determination of Prostate Volume by Transrectal UltrasoundJournal of Urology, 1991
- Prediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical StagingJournal of Urology, 1974